Cutting edge: cross-presentation as a mechanism for efficient recruitment of tumor-specific CTL to the brain.
about
Focus on TILs: Prognostic significance of tumor infiltrating lymphocytes in human gliomaImmunotherapy for primary brain tumors: no longer a matter of privilegeKeeping it in check: chronic viral infection and antiviral immunity in the brainIdentification of a glioma antigen, GARC-1, using cytotoxic T lymphocytes induced by HSV cancer vaccine.Synergy between CD8 T cells and Th1 or Th2 polarised CD4 T cells for adoptive immunotherapy of brain tumoursGlioma growth inhibition by neurostatin and O-But GD1bImmunotherapy for human glioma: innovative approaches and recent results.Tumor-infiltrating immune cells promoting tumor invasion and metastasis: existing theories.Tumor stress, cell death and the ensuing immune response.Anti-tumor activity and trafficking of self, tumor-specific T cells against tumors located in the brainContribution of CD8 T lymphocytes to the immuno-pathogenesis of multiple sclerosis and its animal models.Immunotherapy of diffuse gliomas: biological background, current status and future developments.Cancer immunoediting in malignant glioma.Neonatal and adult microglia cross-present exogenous antigens.Preferential migration of regulatory T cells mediated by glioma-secreted chemokines can be blocked with chemotherapy.Rejection of RG-2 gliomas is mediated by microglia and T lymphocytes.The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses.Myxoma virus combined with rapamycin treatment enhances adoptive T cell therapy for murine melanoma brain tumors.Efficiently stimulated adult microglia cross-prime naive CD8+ T cells injected in the brain.A randomized controlled phase II trial of vaccination with lysate-loaded, mature dendritic cells integrated into standard radiochemotherapy of newly diagnosed glioblastoma (GlioVax): study protocol for a randomized controlled trial.Toll-like receptor triggered dendritic cell maturation and IL-12 secretion are necessary to overcome T-cell inhibition by glioma-associated TGF-beta2.
P2860
Q24615166-304E1004-D6AB-458D-8733-E20FAF7A732FQ27002510-14C464EB-DA81-47DB-9C4C-2E32A89CBD23Q27787368-BC050AAC-0D64-4F91-BEB0-F22C93B580F2Q33223046-44569AF1-61ED-41E4-8AD3-58E29E36BFC9Q34744875-F2FA3C44-7977-4854-8874-FA97FDC77131Q34992507-2D6F3396-F972-493A-9F50-4FD3C2BC0034Q36284489-FD422602-02F0-4608-8FEB-7C9CF71598E4Q36587186-850EC7A7-830E-4A0E-A7EF-B1DF201A6B0AQ36997144-76218DBE-950B-4902-9AD5-DAD91CDA49C6Q37037932-D9F41498-8825-4704-B921-42C390D47DC5Q37313736-08C4111A-B6CD-4AC1-902B-BE8A1BCB1518Q37594831-E35ACB88-3EC0-4CD2-A0E2-13F36B324D39Q37986999-ED6383C6-0591-4331-BE54-994DD93D043AQ40068623-3E544936-0A3E-4BB3-95B4-89C16F67CA20Q40128449-3E98186B-860A-40DC-BD7C-4430F2A73EF4Q40292911-A215DD0A-76E1-497E-8212-863B054F29C7Q41779891-BF5F889E-928E-4EB1-9419-77264CF4C8E3Q42118566-64837536-D5A8-450C-8F00-E5A698B7C12DQ45990565-737F93FC-4EC8-4D71-8295-0DCD9418CA24Q54980235-6AB9FFC4-6DDA-4C60-989F-6F2DE72DC84DQ55469112-821D3FD2-4F29-487D-B993-0EF2BE07B381
P2860
Cutting edge: cross-presentation as a mechanism for efficient recruitment of tumor-specific CTL to the brain.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Cutting edge: cross-presentati ...... mor-specific CTL to the brain.
@en
Cutting edge: cross-presentati ...... mor-specific CTL to the brain.
@nl
type
label
Cutting edge: cross-presentati ...... mor-specific CTL to the brain.
@en
Cutting edge: cross-presentati ...... mor-specific CTL to the brain.
@nl
prefLabel
Cutting edge: cross-presentati ...... mor-specific CTL to the brain.
@en
Cutting edge: cross-presentati ...... mor-specific CTL to the brain.
@nl
P2093
P1476
Cutting edge: cross-presentati ...... umor-specific CTL to the brain
@en
P2093
Frédérick Masson
Nicolas de Tribolet
Pierre-Yves Dietrich
Rick Wilmotte
Wilma Di Berardino-Besson
P304
P356
10.4049/JIMMUNOL.171.5.2187
P407
P577
2003-09-01T00:00:00Z